{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:37:19Z","timestamp":1792143439717,"version":"4.4.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1001\/jama.2021.4542","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T11:01:14Z","timestamp":1620126074000},"page":"1755","source":"Crossref","is-referenced-by-count":32,"title":["Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission"],"prefix":"10.1001","volume":"325","author":[{"given":"Siri","family":"Lillegraven","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Paulshus Sundlis\u00e6ter","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Birgitte","family":"Aga","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge C.","family":"Olsen","sequence":"additional","affiliation":[{"name":"Clinical Trial Unit, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallvard","family":"Fremstad","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u00c5lesund Hospital, Helse M\u00f8re og Romsdal HF, \u00c5lesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Spada","sequence":"additional","affiliation":[{"name":"Revmatismesykehuset AS, Lillehammer, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Magne","family":"Madland","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"H\u00f8ili","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital \u00d8stfold HF, Moss, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnstein","family":"Bakland","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of North Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se","family":"Lexberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Drammen Hospital, Vestre Viken HF, Drammen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Johanne Widding","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, S\u00f8rlandet Hospital HF, Kristiansand, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Myrnes","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Helgelandssykehuset Mo i Rana, Mo i Rana, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Haukeland","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Martina Hansens Hospital, B\u00e6rum, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud-Kristine Aga","family":"Ljos\u00e5","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u00c5lesund Hospital, Helse M\u00f8re og Romsdal HF, \u00c5lesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Moholt","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Uhlig","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Department of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"joi210033r1","doi-asserted-by":"publisher","first-page":"i4205","DOI":"10.1136\/bmj.i4205","article-title":"Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial.","volume":"354","author":"Haavardsholm","year":"2016","journal-title":"BMJ"},{"issue":"10","key":"joi210033r2","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3899\/jrheum.121515","article-title":"Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.","volume":"40","author":"Combe","year":"2013","journal-title":"J Rheumatol"},{"issue":"2","key":"joi210033r3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/annrheumdis-2013-204020","article-title":"Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.","volume":"74","author":"Aga","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8998","key":"joi210033r4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(96)90535-8","article-title":"Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.","volume":"347","author":"ten Wolde","year":"1996","journal-title":"Lancet"},{"issue":"12","key":"joi210033r5","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1136\/annrheumdis-2016-209272","article-title":"Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.","volume":"75","author":"Kuijper","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"joi210033r6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/ard.2010.136556","article-title":"Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"joi210033r7","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","article-title":"Sustained remission with etanercept tapering in early rheumatoid arthritis.","volume":"371","author":"Emery","year":"2014","journal-title":"N Engl J Med"},{"issue":"9914","key":"joi210033r8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.","volume":"383","author":"Smolen","year":"2014","journal-title":"Lancet"},{"key":"joi210033r9","doi-asserted-by":"publisher","first-page":"h1389","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.","volume":"350","author":"van Herwaarden","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"joi210033r10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","article-title":"Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.","volume":"75","author":"van Vollenhoven","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"joi210033r11","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative.","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"joi210033r12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.","volume":"49","author":"van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"joi210033r13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/rheumatology\/35.11.1101","article-title":"Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score.","volume":"35","author":"Prevoo","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"3","key":"joi210033r14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"joi210033r15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.v38:1","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"5","key":"joi210033r16","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"joi210033r17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice.","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"joi210033r18","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"147","key":"joi210033r19","first-page":"393","article-title":"Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.","volume":"37","author":"Ritchie","year":"1968","journal-title":"Q J Med"},{"issue":"9","key":"joi210033r20","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3899\/jrheum.090358","article-title":"Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing.","volume":"36","author":"Fries","year":"2009","journal-title":"J Rheumatol"},{"issue":"1","key":"joi210033r21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play.","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"issue":"6","key":"joi210033r22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/ard.2010.142901","article-title":"Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative.","volume":"70","author":"Gossec","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"joi210033r23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"11","key":"joi210033r24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1136\/ard.2011.152926","article-title":"Examination of intra and interrater reliability with a new ultrasonographic reference atlas for scoring of synovitis in patients with rheumatoid arthritis.","volume":"70","author":"Hammer","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"joi210033r25","first-page":"743","article-title":"How to read radiographs according to the Sharp\/van der Heijde method.","volume":"26","author":"van der Heijde","year":"1999","journal-title":"J Rheumatol"},{"issue":"6","key":"joi210033r26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/(ISSN)1529-0131","article-title":"American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis.","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"1","key":"joi210033r27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria.","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"6","key":"joi210033r30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse effects of low-dose methotrexate: a randomized trial.","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"joi210033r31","first-page":"S188","article-title":"A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases.","volume":"23","author":"Kvien","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"joi210033r32","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","article-title":"Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.","volume":"75","author":"Schett","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"joi210033r33","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","article-title":"Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.","volume":"78","author":"van Mulligen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"joi210033r34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","article-title":"Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.","volume":"75","author":"Haschka","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"joi210033r35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2020-217811","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"joi210033r36","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/ard.2005.039859","article-title":"Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission.","volume":"65","author":"Landew\u00e9","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"joi210033r28","volume-title":"Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA)","author":"US Department of Heath and Human Services","year":"1999"},{"key":"joi210033r29","volume-title":"Non-inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry","author":"US Department of Health and Human Services","year":"2016"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2779548\/jama_lillegraven_2021_oi_210033_1620137997.89481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T11:01:21Z","timestamp":1620126081000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2779548"}},"subtitle":["The ARCTIC REWIND Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":36,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,5,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.4542","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,4]]}}}